Glenmark launches Prasugrel for heart patients in India

Glenmark Pharmaceuticals today announced the India launch of 'Prasugrel', a new anti-platelet drug for heart patients.

The tablet, to be marketed as 'Aplet', is an oral anti-platelet medicine specifically for patients who have undergone an angioplasty procedure to open up a blocked heart artery after experiencing a heart attack or heart-related chest pains.

This condition is known medically as acute coronary syndrome with PCI (percutaneous coronary intervention).
 
Prasugrel (Aplet) offers an effective alternative to current oral anti-platelet drugs, which have several limitations, including slow onset of action, inter-patient variability and possibility of poor or no response in some patients, especially those who are diabetic, as per Glenmark.

"With the introduction of Aplet, Glenmark has provided a superior anti-platelet medicine for the management of patients who have acute coronary syndrome with PCI," Rajeev Sibal, vice president - India formulations, Glenmark Pharmaceuticals Limited, said.

"Glenmark will continue its efforts of introducing first to market products across therapeutic categories in the country," he added.

The estimated market size for this product is Rs300 crore.

Based in Mumbai, Glenmark is a research-driven, integrated pharmaceutical company.